The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Therapeutic Potential of Spirooxindoles as Antiviral Agents
Open accessAbstract
Antiviral therapeutics with profiles of high potency, low resistance, panserotype, and low toxicity remain challenging, and obtaining such agents continues to be an active area of therapeutic development. Due to their unique three-dimensional structural features, spirooxindoles have been identified as privileged chemotypes for antiviral drug development. Among them, spiro-pyrazolopyridone oxindoles have been recently reported as potent inhibitors of dengue virus NS4B, leading to the discovery of an orally bioavailable preclinical candidate (R)-44 with excellent in vivo efficacy in a dengue viremia mouse model. This review highlights recent advances in the development of biologically active spirooxindoles for their antiviral potential, primarily focusing on the structure-activity relationships (SARs) and modes of action, as well as future directions to achieve more potent analogues toward a viable antiviral therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Galliford, C. V., & Scheidt, K. A. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200701342 · Cited by 2,429
The IMpact-RSV Study Group (1998) · Pediatrics · doi:10.1542/peds.102.3.531 · Cited by 1,961
Escape from Flatland 2: complexity and promiscuity
Lovering, F. (2013) · MedChemComm · doi:10.1039/c2md20347b · Cited by 1,444
Spiroindolones, a Potent Compound Class for the Treatment of Malaria
Rottmann, M., McNamara, C., Yeung, B. K. S., Lee, M. C. S., Zou, B., Russell, B., Seitz, P., Plouffe, D. M., Dharia, N. V., Tan, J., et al. (2010) · Science · doi:10.1126/science.1193225 · Cited by 1,206
A decade of fragment-based drug design: strategic advances and lessons learned
Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,064
The use of spirocyclic scaffolds in drug discovery
Zheng, Y., Tice, C. M., & Singh, S. B. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.06.081 · Cited by 1,036
Spirooxindoles: Promising scaffolds for anticancer agents
Yu, B., Yu, D.-Q., & Liu, H.-M. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.06.056 · Cited by 867
Flexner, C. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381808 · Cited by 852
Cited by
Catalytic asymmetric synthesis of spirooxindoles: recent developments
Mei, G.-J., & Shi, F. (2018) · Chemical Communications · doi:10.1039/c8cc02364f · Cited by 467
An overview of spirooxindole as a promising scaffold for novel drug discovery
Zhou, L.-M., Qu, R.-Y., & Yang, G.-F. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1733526 · Cited by 316
Metadata
- Authors
- Ye, N., Chen, H., Wold, E. A., Shi, P.-Y., & Zhou, J.
- Venue
- ACS Infectious Diseases
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-05-05
- Volume
- 2
- Issue
- 6
- Pages
- 382-392
- ISSN
- 2373-8227 (ISSN-L)
- OpenAlex
- W2345105659
- Cited by
- 493
- References
- 64
- FWCI
- 20.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic Potential of Spirooxindoles as Antiviral Agents. https://app.cochat.ai/papers/10.1021/acsinfecdis.6b00041
- The paper
- Ye, N., Chen, H., Wold, E. A., Shi, P.-Y., & Zhou, J. (2016). Therapeutic Potential of Spirooxindoles as Antiviral Agents. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.6b00041
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.